A 52-year-old woman was admitted to our hospital suffering from 
| INTRODUC TI ON
is still lacking. Recently, the novel molecular-targeted therapeutic agent, everolimus, an orally active mammalian target of rapamycin (mTOR) inhibitor, has been shown to have antitumor growth effects in patients with pNET. 3 Here, we report a case of inoperable metastatic malignant insulinoma with marked reduction of liver metastases and good hypoglycemia control by monthly intramuscular administration of octreotide LAR and once-daily oral administration of everolimus.
| C A S E REP ORT
A 52-year-old woman was admitted to our hospital suffering from epigastric pain. She experienced several intermittent hypoglycemic episodes for over half a year. During admission, she presented with neurological symptoms of hypoglycemia. Her simultaneous plasma glucose level was 37 mg/dL with inappropriately high serum IRI level (45.8 μIU/mL) and Fajan's index (IRI/plasma glucose) of 1.24 (normal, <0.30). ACTH and cortisol levels were within the respective normal ranges. Anti-insulin antibodies were negative. There was no history of use of hypoglycemic agents, alcohol abuse, or liver disease. On 100 μg octreotide loading test, plasma glucose was increased, while plasma IRI was decreased, suggesting that octreotide may be useful to control hypoglycemia. More than, we introduced 
| D ISCUSS I ON
Surgical resection is the first choice of therapy for benign and malignant insulinomas, where possible. However, medical therapy is indicated in patients with unresectable malignant insulinoma. In patients with NEC G1/G2, molecular-targeted treatment is recommended to decrease tumor growth progression. Moreover, medical therapy is required to control hypoglycemia due to insulin hypersecretion. Treatment to inhibit insulin hypersecretion includes the use of somatostatin analog or diazoxide. Somatostatin, a ubiquitous polypeptide, inhibits the secretion of many hormones including insulin, glucagon, growth hormone, and gastrin. 4 Octreotide and lanreotide bind mainly to SSTR subtypes 2 and 5, and less to SSTR subtype 3. 5 In insulinoma, the expression level of SSTR subtypes 2 and 5 is high, so the rate is about 70%. 6 Therefore, the patients with pNET positive for anti-SSTR2 immunostaining are responsive to somatostatin analog. 7 Octreotide has been reported to inhibit tumor growth in patients with midgut NETs (PROMID study). 8 Lanreotide has been also reported to have the effect of antitumor growth in pNETs (CLARINET study). Octreotide was used in our case, because octreotide is the only somatostatin analog that is used in functioning pNET at that time. However, antitumor effect of octreotide remains to be established in pNET including insulinoma.
Recently, everolimus, an orally active mammalian target of rapamycin (mTOR) inhibitor, has been shown to have antitumor growth effects in patients with pNET. 3 The protein of mTOR is a serine/threonine kinase that regulates cell growth, proliferation, and metabolism. In pNETs, the expression of mTOR protein is upregulated. 9 The expression and activity of mTOR and its downstream targets such as 4EBP1, S6, and eIF4E are strongly dependent on enhanced proliferative capacity and metastatic status in gastroenteropancreatic neuroendocrine foregut and midgut tumors. Evidence from preclinical studies suggests that the combination of pasireotide and everolimus may be synergistic by dual inhibition of insulin-like growth factor-1 (IGF-1) and mTOR signaling. 10 The combination treatment may be more effective than each treatment. The maintenance therapy with somatostatin analog and mTOR inhibitor combination treatment may play a significant role in tumor control in patients with advanced NET, unless hyperglycemia induced. Further studies in larger numbers of insulinoma patients are required to support this suggestion.
| CON CLUS ION
We reported a case of inoperable metastatic malignant insulinoma, in which liver metastases were markedly reduced and hypoglycemia was well controlled by monthly intramuscular administration of octreotide LAR and once-daily oral administration of everolimus.
Combination treatment with somatostatin analog and mTOR inhibitor may be another effective approach in inoperable metastatic malignant insulinoma.
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